Bethan A. Cole

This study identifies eight structurally diverse KCNT1 channel inhibitors through virtual screening and experimental validation, offering potential new treatments for KCNT1-associated epilepsy.

This study identifies a potent and selective TRPC3 inhibitor, GSK2820986A, and elucidates its binding mechanism through molecular dynamics and functional assays.

This study identifies two existing drugs that reduce KCNT1 channel activity and seizure activity in Drosophila models, suggesting potential new treatments for KCNT1-epilepsy.

This paper identifies a molecular switch in the RCK2 domain of KNa1.1 channels that mediates sodium-dependent activation through conformational changes involving specific amino acid residues.

This study investigates how epilepsy-causing KCNT1 variants increase KNa1.1 channel activity by disrupting activation and selectivity filter gates.